Iatrogenic Baclofen Neurotoxicity in ESRD: Recognition and Management. Issue 5 (21st June 2015)

• Record Type: Journal Article
• Authors: Roberts, John K.; Westphal, Scott; Sparks, Matthew A.
• Is Part Of: Seminars in dialysis. Volume 28:Issue 5(2015)
• Page Start: 525
• Page End: 529
• Publication Date: 2015-06-21
• Subjects: Hemodialysis -- Periodicals; Dialysis -- Periodicals; Renal Dialysis -- Periodicals; 617.461059
• DOI: 10.1111/sdi.12400
• Languages: English
• ISSNs: 0894-0959

Abstract

<abstract abstract-type="main" id="sdi12400-abs-0001"> <title>Abstract</title> <p>Baclofen is an oral derivative of gamma‐aminobutyric acid (GABA) used to treat muscular spasticity from disorders of the central nervous system. However, it is also being used for a variety of other conditions such as musculoskeletal pain, myoclonus, and alcohol withdrawal. The elimination of baclofen is heavily dependent on intact renal function, and the contraindication for use in patients with insufficient renal function is not well recognized by healthcare providers. Here, the authors report a series of mild to severe cases of baclofen intoxication in patients with end‐stage renal disease. In all cases, baclofen was initiated by either inpatient or outpatient healthcare providers and the patients generally presented with altered mentation, somnolence, and/or respiratory depression. All patients were treated with aggressive hemodialysis and made a full recovery. This paper will briefly review the literature regarding baclofen intoxication, safety of baclofen use in renal disease, and efficacy of extracorporeal therapy in the treatment of baclofen intoxication.</p> </abstract>